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One of the most important roles the Brazilian Society of
Biotechnology - SBBIOTEC can play is to organize the
Biotechnology Sector. The Brazilian Biotechnology Net-
work aims at the academic sector. The academic sector is
represented by 48 Graduate Courses registered at CAPES
(Coordenação de Aperfeiçoamento de Pessoal de Nivel
Superior) /Ministry of Education, specifically in the area
of Biotechnology. There are an even larger number of
Graduate Courses related to Biotechnology but registered
at CAPES in other areas such Biochemistry, Genetics.
Pharmacology among others. So the Biotechnology aca-
demic sector is not irrelevant. However less than 1% of
the scientific output in Biotechnology in Brazil reaches
the market. The main goal of the Brazilian Biotechnology
Network is to increase the visibility of the science that is
produced in the Biotechnology sector in Brazil and
related areas of application to catalyse the transfer of
innovative scientific results to the industry. The academic
and the private biotechnology sector do not interact. For
this reason the number of scientists in Brazil hired by the
private sector is small although Brazil graduates more
than 1000 PhDs /year This reality differs considerably
from the context in the United States that for this reason
and others control 70% of the Biotechnology business in
the world. In 2011 [1] CEBRAP and BRBIOTEC mapped
237 Biotechnology companies in Brazil. Efforts of this
nature happen spasmodically. How was the Biotechnol-
ogy sector structured in Brazil in 2011? 85% of the Bio-
technology enterprises in Brazil had less than fifty
employees and 56% of the revenues of these companies
were around 1 million US $/year. Eighty % of these com-
panies are located in three states: São Paulo, Minas Ger-
ais and Rio de Janeiro. Most companies do not know that
a network that I established in the North East of Brazil -
RENORBIO deposited over one hundred and fifty patent
applications in the last seven years and established 10
startup companies. This network and two others I estab-
lished recently, one in the Amazonian region (Bioamazo-
nia) and the other in West, the Savannah region in Brazil
have web system and their graduate courses operate as
Networks. RBB is intended to cover the whole country
using the same software with some adjustments. Probably
a larger number of patent applications and startup compa-
nies can be made visible if we extend the same software to
the whole academic sector in Brazil thru the RBB. The soft-
ware offer in addition: students, professors, disciplines,
scientific outputs, patents and startup companies. Even
small companies might be stimulated to hire PhDs holding
patent applications. The software not only cites patent
applications but the development of process in the patent
Agencies. The RBB will be funded by the FAP/DF (Funda-
ção de Amparo a Pesquisa do Distrito Federal), not only
the software to be developed by Hiragy TI but the monitor-
ing of the system at SBBIOTEC : www.sbbiotec.org.br.
During the last three years I have contributed to the
Bioentrepreneur blog of Nature Biotechnology: http://
blogs.nature.com/tradesecrets/author/lbarreto. In my last
contribution published in September 26 I state that the
efforts to develop biotechnology in Brazil now exceeds
three decades. This analysis that deals with Opportunities
and Limitations for Biotechnology Innovation in Brazil is
part of an eBook published by Bentham Books [2] I have
written this e-book now because Brazil has emerged finan-
cially and now has more opportunities in biotech than pre-
viously. The book is intended for those who want to know
some of the history of biotech in Brazil, and to ponder the
power of this technology and the opportunities we now
have in our hands. Brazil may become a relevant actor in
this area internationally, taking advantage of some circum-
stances here that are not available in other countries, parti-
cularly our biodiversity.
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Since the seventies Brazil started training young scien-
tists in plant genetic engineering and molecular biology,
hoping to incorporate this nascent technology into
EMBRAPA’s (Brazilian Enterprise for Agricultural
Research) plant breeding efforts. This work I started in
the 80s took place at The National Center for Genetic
Resources and Biotechnology (CENARGEN) and added
to the efforts of a dozen excellent geneticists. The soy-
bean revolution in Brazil was brought about by Romeu
Kihl; aluminum-resistant corn developed for the acidic
“cerrado” soil was created by Ricardo Magnavacca; and
the foundations of maize breeding had been previously
done by the late Ernesto Paterniani. Eleuzio Curvello did
cotton, and Alcides Carvalho, coffee, for 52 years of his
life. Dalmo Giacometti and Silvio Moreira, citrus. Marci-
lio Dias and Hiroshi Ikuta are the fathers of the vegetable
genetics; Raul Moreira tackled banana; Ady Raul da Silva,
wheat. Finally Frederico Menezes Veiga, sugarcane in the
North of Rio de Janeiro. Through all this, plant breeding
has continuously built cultivars to feed our seed industry.
High-tech seeds and low-cost farming practices were the
result of seed laws and plant breeder’s law in Brazil. The
end result is that Brazil can competitively produce nearly
200 million tons of grain because it is cheap for the
farmer. Brazil tried to follow the growth of commercial
biology. In the ‘90s, Brazil introduced protections for
intellectual property around genetics and plant breeding
rights as aid before, but that efforts were not sufficient,
because Brazil suffered through rampant inflation for
decades even as it invested in Biotechnology.
The e-Book describes adjustments that must be made to
assure the success of our investments, particularly to the
laws and regulatory framework. The book investigates the
immense possibilities of agricultural biotech in Brazil,
partly because the mechanisms of public private interac-
tions are well designed and in operation. The public per-
ception in Brazil and many other countries has turned
against genetic engineering for political and ideological
reasons: when the first engineered soybean resistant to gly-
phosate was released commercially a campaign against
transgenic plants prevented the application of this technol-
ogy in agriculture for almost a decade in Brazil. However,
the world adopted recombinant DNA technology in the
pharmaceutical area and most products utilized interna-
tionally by the public in this industry (including Brazil) are
genetically engineered. There is a twisted public percep-
tion problem in the Ag Biotech that has to be faced glob-
ally, particularly in Europe. The only solution is to focus
biotech on the issues surrounding poverty (discussed in
one of the e-book’s chapters).
In the pharmaceutical industry in Brazil the context is
quite different. Brazil lags behind many developed and
emerging countries, and does not have an equivalent to
EMBRAPA in the public pharmaceutical area. The area is
growing, however (in 2011, up 14%), because the market
is a demanding one. We import active principles from
other countries and commercialize foreign products for
our market here. So we are growing without innovation.
There are initiatives that pull large, nationally funded
companies together as consortia, and which propose
“biosimilars” for monoclonal antibodies with expiring
patents, but there is no innovation as an initiative. Brazil
has no contract manufacturing organization, and not one
CMO or cGMP-facility. Because of this, Brazil cannot
scale up its pharmaceutical products, nor can it properly
conduct the clinical studies needed for registration at
ANVISA (http://portal.anvisa.gov.br/wps/portal/anvisa-
ingles). Brazil has never produced a block buster or regis-
tered a pharmaceutical product at the FDA. Large cor-
porations in general do not invest in Brazil, claiming
Brazil’s patent laws are not adequate. And finally, Brazil
has no risk capital funds (Burrill & Co is a solitary actor).
There is a movement in the right direction, however.
The government is supplying loans for biotech projects,
allowing repayment in 10 to 15 years, with subsidized
interest and the absence of capital payment for 3 to
5 years. Also, the federal government and private sector
are funding scholarships to train 100,000 students in the
next five years at all levels from high school to PhD. This
is great news, but there are many more problems that
need to be resolved in the coming decade. In 2005 Brazil
sanctioned an Innovation Law. We estimated that in ten
years 10 billion US$ would flow to the Biotechnology sec-
tor. The decade is almost over and funds never came by.
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